Vitiligo: Pathogenesis, clinical variants and treatment approaches

Iannella, Giannicola; Greco, Antonio; Didona, Dario; Didona, Biagio; Granata, Guido; Manno, Alessandra; Pasquariello, Benedetta; Magliulo, Giuseppe

doi:10.1016/j.autrev.2015.12.006

Cited by 165 publications

(175 citation statements)

References 142 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…(2) Vitiligo is characterized by depigmentation of the skin, with predominantly Th1-mediated inflammation. (3)…”

Section: Introductionmentioning

confidence: 99%

Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ Health Study 2

Drucker

Thompson

et al. 2017

Allergy

View full text Add to dashboard Cite

We aimed to determine the risk of AA and vitiligo associated with AD in a large cohort of US women, the Nurses’ Health Study 2. We used logistic regression to calculate age- and multivariate-adjusted odds ratios to determine the risk of incident AA and vitiligo associated with AD diagnosed in or before 2009. A total of 87,406 and 87,447 participants were included in the AA and vitiligo analyses, respectively. A history of AD in 2009 was reported in 11% of participants. There were 147 incident cases of AA and 98 incident cases of vitiligo over 2 years of follow-up. AD was associated with increased risk of developing AA (OR 1.80, 95% CI 1.18–2.76) and vitiligo (OR 2.14, 95% CI 1.29–3.54) in multivariate models. In this study of US women, AD was associated with increased risk of incident vitiligo and AA in adulthood.

show abstract

“…(2) Vitiligo is characterized by depigmentation of the skin, with predominantly Th1-mediated inflammation. (3)…”

Section: Introductionmentioning

confidence: 99%

Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ Health Study 2

Drucker

Thompson

et al. 2017

Allergy

View full text Add to dashboard Cite

show abstract

“…On the contrary, vitiligo is a chronic skin condition characterized by portions of the skin losing their pigment when skin pigment cells die or are unable to function [28,29]: the surrounding unaffected skin may be lightened to match to the tone of the affected skin.…”

Section: Why Such a Practice?mentioning

confidence: 99%

Skin Whitening Cosmetics: Feedback and Challenges in the Development of Natural Skin Lighteners

et al. 2016

View full text Add to dashboard Cite

Abstract:With the public's growing interest in skin whitening, lightening ingredients only used under dermatological supervision until recently, are more and more frequently incorporated into cosmetic formulas. The active agents that lighten skin tone are either natural or synthetic substances, and may act at various levels of melanogenesis. They are used to treat various skin pigmentation disorders or simply to obtain a lighter skin tone as whiter skin may be synonymous of wealth, health, youth, and/or beauty in different cultures. However, recent studies demonstrated the adverse effects of some of these ingredients, leading to their interdiction or restricted use under the European Directive and several other international regulations. After an overview of skin whitening practices and the associated risks, this article provides insight into the mechanisms involved in melanin synthesis and the biological assays available to attest the lightening activity of individual ingredients. The legislation dealing with the use of skin lighteners is then discussed. As traditional depigmenting agents such as hydroquinone and corticosteroids are of safety concern, the potential of natural extracts has been investigated more and more; finally, a synthesis of three years of research in our laboratory for such plant extracts will be given.

show abstract

“…Its prevalence is between 0.5% and 2% worldwide, and its inheritance is polygenic (Ghorbani & Masoodi, 2013;Iannella et al, 2016). Its prevalence is between 0.5% and 2% worldwide, and its inheritance is polygenic (Ghorbani & Masoodi, 2013;Iannella et al, 2016).…”

mentioning

confidence: 99%

Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double‐blind clinical trial study

Dailami

Hosseini

Rokni

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Numerous studies have demonstrated that the pigmentation of iris and around the eyelid is a common side effect of latanoprost, a prostaglandin F2alpha analogue used in the treatment of glaucoma. Hence, the authors decided to study the effectiveness of topical latanoprost on vitiligo patches around the eyelid. In this randomized, double-blind, clinical trial study, 31 patients with vitiligo vulgaris and focal vitiligo involving the eyelids were evaluated. Patients were randomly divided into two groups. First group received topical latanoprost gel twice daily for 12 weeks, whereas the second group received placebo with the same protocol. To evaluate severity of the disease the VIDA rating system was used. Serial photos of the patches were taken to compare and evaluate the repigmentation percentage of the patches. The patients in both groups had almost similar VIDA score (p > .05). First group showed improved pigmentation, whereas participants in the second group did not show any improvement in the pigmentation. The group treated with latanoprost showed significant reduction in the symptoms of the disease, whereas those treated with placebo did not show any alteration (p > .05). No significant complications were observed in either groups. Latanoprost proved effective in treating vitiligo disease involving eyelids.

show abstract

Vitiligo: Pathogenesis, clinical variants and treatment approaches

Cited by 165 publications

References 142 publications

Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ Health Study 2

Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses’ Health Study 2

Skin Whitening Cosmetics: Feedback and Challenges in the Development of Natural Skin Lighteners

Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double‐blind clinical trial study

Contact Info

Product

Resources

About